[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620595":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":53,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":19,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Erlangen-Nürnberg Medical School","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Assessment of retinal vessels","OCTA and SLDF based assessment of retinal vasculature",[12],"Diagnostic Test: Retinal vascular assessment using OCTA and SLDF",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Retinal vascular assessment using OCTA and SLDF","Assessment of retinal capillary density using OCTA and SLDF",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Agnes Bosch, MD","Clinical Research Center, Department of Nephrology and Hypertension, Universityhospital Erlangen","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","+49 9131 8536245","agnes.bosch@uk-erlangen.de",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Dennis Kannenkeril, MD","+49 911 80099760","CRC.M4@uk-erlangen.de",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Erlangen Nuremberg","RECRUITING","Erlangen","Bavaria","91054","Germany","DE",{"type":44,"coordinates":45},"Point",[46,47],11.00783,49.59099,{"lat":47,"lon":46},[50],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":33},{"type":52,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[54],{"name":55,"class":6},"German Diabetes Association","100620595","octa-in-cardiovascular-disease-and-healthy-controls-100620595",false,"NCT07359664","OCTA in Cardiovascular Disease and Healthy Controls","Optical Coherence Tomography Angiography (OCTA) for the Assessment of Retinal Capillary Density in Patients With Cardiovascular Disease and a Healthy Control Group","Inclusion Criteria for patients with cardiovascular disease:\n\n* cardiovascular disease defined as one or more of the following: arterial hypertension, type 2 diabetes mellitus, chronic kidney disease, heart failure\n\nInclusion Criteria for healthy individuals:\n\n* BMI 18-29.9 kg\u002Fm2\n* Non-smoker\n* Good general health, as determined by study personnel based on assessments of previous visits, including anamnesis, vital signs, physical examination and clinical laboratory parameters.\n\nExclusion criteria for patients with cardiovascular disease:\n\n* Active ophthalmological (retinal) disease resulting in impaired visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).\n\nExclusion criteria for healthy individuals:\n\n* Active ophthalmological (retinal) disease with reduced visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).\n* clinically relevant deviation in physical examination, vital signs, or laboratory parameters (based on the physician's clinical judgement).\n* a clinically relevant history of cardiovascular disease or any other previously known cardiovascular disease\n* History of clinically relevant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine or other diseases\n* office blood pressure above or equal to 140\u002F90 mmHg\n* Office heart rate outside of the following range: 50-99 bpm\n* regular intake of any medication for the treatment of cardiovascular diseases (e.g. antihypertensive or antidiabetic medication) within one month before study inclusion\n* alcohol or drug abuse",true,"ALL","18 Years","75 Years",{"count":68,"type":69},64,"ESTIMATED","INTERVENTIONAL",[72],"NA","This prospective clinical study will involve the non-invasive assessment of retinal vessels using OCTA (Cirrus OCT 6000 AngioPlex) and scanning laser Doppler flowmetry (SLDF) in patients with cardiovascular disease and healthy individuals. The study will be conducted at the Clinical Research Centre (CRC), Department of Nephrology and Hypertension at the University of Erlangen-Nuremberg.",[75,76],"Patients With Cardiovascular Disease","Healthy Participants",[78,79,80,81],"arterial hypertension","type 2 diabetes mellitus","chronic kidney disease","heart failure","2026-01-15",{"date":84,"type":85},"2026-01-22","ACTUAL",{"date":87,"type":85},"2025-12-01",{"date":89,"type":69},"2027-03",{"name":5,"class":6},1]